• Ana Luiza Berwanger, Astrid Finet, Hady El Hachem, Soizic le Parco, Laetitia Hesters, and Michael Grynberg.
• AP-HP, Service de Gynécologie-Obstétrique & Médecine de la Reproduction, Hôpital Antoine Béclère, Clamart, F-92141, France.
• Future Oncol. 2012 Dec 1;8(12):1567-73.

AbstractAs antineoplastic treatments have become more successful, an increasing number of women with cancer survive to endure the long-term consequences of chemotherapy. One of the most important of these consequences in young females is premature ovarian failure and infertility. Owing to increasing survival rates, many of these young women are seeking methods to preserve their fertility. Currently, embryo/oocyte cryopreservation obtained after controlled ovarian stimulation appears to provide the best fertility preservation option. However, patients may not have enough time to undergo ovarian stimulation prior to chemotherapy and/or have contraindications to exogenous gonadotropin administration owing to estrogen-dependant tumors. In vitro maturation of oocytes is an attractive alternative for fertility preservation in cancer patients because it does not require ovarian stimulation and it can be performed at any time of the menstrual cycle. In addition, this technique can be combined with ovarian tissue cryobanking. In this review, we discuss the position of in vitro maturation of oocytes in the fertility preservation strategy in young women.

25 keywords...

hide…